We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
Green Plains
GPRE
$1.09B
| $349K | ﹤0.01% |
11,445
-659
| -5% | -$20.3K |
|
1927
Atlanta Braves Holdings Series B
BATRK
$3.25B
| $349K | ﹤0.01% |
10,829
-7,182
| -40% | -$224K |
|
1928
BCB Bancorp
BCBP
$157M
| $348K | ﹤0.01% |
19,339
-11,818
| -38% | -$221K |
|
1929
Napco Security Technologies
NSSC
$1.41B
| $348K | ﹤0.01% |
12,648
-249
| -2% | -$6.72K |
|
1930
Vericel Corp
VCEL
$2.29B
| $347K | ﹤0.01% |
13,174
+40
| +0.3% | +$952 |
|
1931
POSCO
PKX
$17.3B
| $346K | ﹤0.01% |
6,355
-921
| -13% | -$45.6K |
|
1932
Nicolet Bankshares
NIC
$3.68B
| $346K | ﹤0.01% |
4,332
+1,423
| +49% | +$111K |
|
|
GOOD
1933
Gladstone Commercial Corp
GOOD
$624M
| $343K | ﹤0.01% |
18,557
-23,518
| -56% | -$418K |
|
1934
NextDecade
NEXT
$1.79B
| $341K | ﹤0.01% |
69,109
+2,369
| +4% | +$13.6K |
|
1935
Unifirst Corp
UNF
$5.29B
| $341K | ﹤0.01% |
1,765
+95
| +6% | +$17.4K |
|
1936
Mercury Insurance
MCY
$5.93B
| $340K | ﹤0.01% |
10,024
-16,806
| -63% | -$559K |
|
1937
Hawkins
HWKN
$2.74B
| $338K | ﹤0.01% |
8,766
+260
| +3% | +$10.7K |
|
1938
Lear
LEA
$8.14B
| $337K | ﹤0.01% |
2,719
-8,808
| -76% | -$1.17M |
|
1939
Sunstone Hotel Investors
SHO
$1.99B
| $334K | ﹤0.01% |
34,623
-2,104
| -6% | -$21.7K |
|
|
CHCT
1940
Community Healthcare Trust
CHCT
$434M
| $334K | ﹤0.01% |
+9,334
| New | +$318K |
|
1941
AbCellera Biologics
ABCL
$3B
| $333K | ﹤0.01% |
+32,913
| New | +$380K |
|
1942
Papa John's
PZZA
$792M
| $332K | ﹤0.01% |
4,035
-7,221
| -64% | -$568K |
|
1943
Varonis Systems
VRNS
$4.82B
| $332K | ﹤0.01% |
+13,863
| New | +$317K |
|
1944
Transmedics
TMDX
$2.99B
| $331K | ﹤0.01% |
5,370
-957
| -15% | -$50.9K |
|
1945
H.B. Fuller
FUL
$3.35B
| $331K | ﹤0.01% |
4,624
+108
| +2% | +$7.8K |
|
|
AAMI
1946
Acadian Asset Management
AAMI
$3.26B
| $331K | ﹤0.01% |
16,063
-4,412
| -22% | -$83.3K |
|
1947
AXT Inc
AXTI
$4.79B
| $330K | ﹤0.01% |
+75,417
| New | +$368K |
|
1948
Granite Construction
GVA
$5.47B
| $330K | ﹤0.01% |
+9,400
| New | +$308K |
|
|
SHCR
1949
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $329K | ﹤0.01% |
205,465
+193,096
| +1,561% | +$357K |
|
1950
Heartland Express
HTLD
$912M
| $328K | ﹤0.01% |
21,358
-88,882
| -81% | -$1.37M |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.